Q/c Technologies, Inc. (QCLS) · Nov 20, 2026 · Material agreement
Maturity extended — Series H maturity: March 2, 2027 → September 2, 2027
Q/C Technologies formalizes preferred-stock amendments that extend maturity to September 2027, offering timing relief without fresh capital.
Q/C Technologies is a pre-revenue company shifting from legacy pharmaceuticals toward optical and quantum/laser-based computing, with its main challenge still funding development before commercial adoption.
The filing mainly formalizes an already disclosed financing accommodation. Q/C filed amendments to the Series G and Series H preferred-stock certificates and amended PharmaCyte’s Series G long-term warrants; the amendments became effective upon filing. 〔0〕
The clearest business benefit is more time, not more liquidity. The Series H preferred-stock maturity moves from March 2, 2027 to September 2, 2027. 〔1〕 That delays a major financing or repayment pressure point by six months, but this 8-K does not provide cash, reduce the preferred balance, or advance the optical-computing program.
The control and dilution mechanics are being adjusted, but the economic impact is not fully clear from this filing. The amendments change the amendment provisions and PharmaCyte-specific beneficial-ownership limits, while the warrant amendment retains a 49.99% ownership cap. 〔2〕 The filing does not disclose a new conversion price, cash consideration, or operating milestone tied to these changes.
This is not a fresh surprise. The maturity extension and related warrant exchange had already been disclosed in the November 16, 2026 quarterly filing, so today’s 8-K is chiefly the legal completion of that arrangement rather than a new change in the company’s operating story.
Bottom line: Q/C gets additional time before a preferred-stock maturity deadline, which helps near-term financial flexibility but does not solve the company’s pre-revenue funding and execution challenge. The filing is confirmation, not a meaningful reset of the business story.
Nasdaq bid-price compliance deadline, May 5, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!